Trial Information

This protocol aims to provide long-term follow-up and continued use of research specimens of
patients previously enrolled on gene transfer or other immunotherapy studies at the National
Cancer Institute. Subjects will undergo an annual health history for up to 15 years.

Inclusion Criteria

- INCLUSION CRITERIA:

Subjects who received poxviral vectors (vaccinia and/or fowlpox) or other vaccines
utilizing gene transfer or any other immunotherapeutic agent through an LTIB affiliated
trial at the National Cancer Institute. These studies include (but are not limited to):
00-C-0137, 00-C-0154, 02-C-0218, 03-C-0176, 04-C-0167, 04-C-0246, 05-C-0017, 05-C-0167,
05-C-0229, 07-C-0106, 07-C-0107, 07-C-0188, 08-C-0166, 09-C-0101 and 11-C-0225. Upon
termination of the above protocols, available stored specimens obtained in each of the
protocols listed above will be transferred to this protocol for future research use.

EXCLUSION CRITERIA:

Patients unwilling to participate. (Please note, patients may participate in this
protocol and, at the same time, participate in an active treatment or continuing care
study.)

Type of Study:

Observational

Study Design:

N/A

Principal Investigator

James L Gulley, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

National Cancer Institute (NCI)

Authority:

United States: Federal Government

Study ID:

040274

NCT ID:

NCT00451022

Start Date:

September 2004

Completion Date:

Related Keywords:

Vaccine

Fowlpox

Vaccinia

PSA

CEA

MUC-1

Gene Therapy

Long Term Survivor

Research Specimen

Name

Location

We are a Cancer Social Network, Resource Directory & Education Hub supporting all those affected by cancer. knowcancer.com is intended to be solely for informational purposes and should not be a substitute for professional medical advice, diagnosis or treatment.